Nemolizumab Approved for AD, Prurigo Nodularis in Europe
The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the signaling of interleukin (IL)-31.
Medscape Medical News
source https://www.medscape.com/viewarticle/european-commission-approves-nemolizumab-atopic-dermatitis-2025a100048f?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/european-commission-approves-nemolizumab-atopic-dermatitis-2025a100048f?src=rss
Comments
Post a Comment